Breaking News Instant updates and real-time market news.

SNY

Sanofi

$45.69

-0.15 (-0.33%)

11:40
11/29/17
11/29
11:40
11/29/17
11:40

Sanofi asks regulators to update dengue vaccine label to reflect new information

Sanofi will ask health authorities to update information provided to physicians and patients on its dengue vaccine Dengvaxia in countries where it is approved. The request is based on a new analysis of long-term clinical trial data, which found differences in vaccine performance based on prior dengue infection. Based on up to six years of clinical data, the new analysis evaluated long-term safety and efficacy of Dengvaxia in people who had been infected with dengue prior to vaccination and those who had not. The analysis confirmed that Dengvaxia provides persistent protective benefit against dengue fever in those who had prior infection. For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection. "These findings highlight the complex nature of dengue infection. We are working with health authorities to ensure that prescribers, vaccinators and patients are fully informed of the new findings, with the goal of enhancing the impact of Dengvaxia in dengue-endemic countries," said Dr. Su-Peing Ng, Global Medical Head, Sanofi Pasteur. Dengvaxia is currently indicated in most of the countries for individuals 9 years of age and older living in a dengue-endemic area. In this indicated population, Dengvaxia has been shown to prevent 93% of severe disease and 80% of hospitalizations due to dengue over the 25 month phase of the large-scale clinical studies conducted in 10 countries in Latin America and Asia where dengue is widespread.

  • 18

    Jan

SNY Sanofi
$45.69

-0.15 (-0.33%)

10/31/17
WEDB
10/31/17
NO CHANGE
Target $31
WEDB
Outperform
Voyager Therapeutics price target lowered to $31 from $36 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Voyager (VYGR) to $31 from $36 following Sanofi's (SNY) decision to not opt-in ex-U.S. rights to VY-AADC, despite positive Phase 1 experience, which he views as an assessment of commercial opportunity for gene therapies outside U.S., rather than a reflection of VY-AADC's clinical profile. The analyst expects Voyager to carry VY-AADC to registration in ex-U.S. regions without a partner, although resources will likely be focused on opportunity in U.S. where a stronger reimbursement environment exists. Nierengarten continues to see Voyager shares as undervalued, and reiterates an Outperform rating on the stock.
11/02/17
PIPR
11/02/17
NO CHANGE
Target $540
PIPR
Overweight
Sanofi's Dupixent sales in Q3 'crushed it,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says Sanofi's (SNY) revenue numbers this morning for Dupixent came in well ahead of anyone's expectations. Worldwide Dupixent sales of $87M "crushed it" versus the consensus of $70M and Piper's estimate of $82M, Raymond tells investors in a research note on Regeneron Pharmaceuticals (REGN). The launch continues to show strength, the analyst contends. He has an Overweight rating on Regeneron with a $540 price target.
11/15/17
LEHM
11/15/17
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded Sanofi to Equal Weight from Underweight saying valuation is back to more reasonable levels.
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.

TODAY'S FREE FLY STORIES

OIS

Oil States

$24.68

1.275 (5.45%)

11:52
12/13/17
12/13
11:52
12/13/17
11:52
Recommendations
Oil States analyst commentary  »

Oil States target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BURL

Burlington Stores

$110.92

1.3 (1.19%)

11:50
12/13/17
12/13
11:50
12/13/17
11:50
Options
Burlington draws a bullish option play as shares see strength »

Burlington draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BT

BT Group

$18.04

-0.0501 (-0.28%)

11:49
12/13/17
12/13
11:49
12/13/17
11:49
Upgrade
BT Group rating change  »

BT Group upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHT

Universal Health Realty

$75.28

1.705 (2.32%)

11:45
12/13/17
12/13
11:45
12/13/17
11:45
Conference/Events
Universal Health Realty management to meet with Jefferies »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:40
12/13/17
12/13
11:40
12/13/17
11:40
General news
Bund/T-note spread widening remains intact »

Bund/T-note spread…

CERN

Cerner

$70.36

0.23 (0.33%)

11:39
12/13/17
12/13
11:39
12/13/17
11:39
Periodicals
VA Secretary says contract with Cerner held up by questions, Politico reports »

Veterans Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:34
12/13/17
12/13
11:34
12/13/17
11:34
Hot Stocks
PlainSite says Credit Acceptance disclosures belie 'deeply flawed' model »

In a "Reality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$287.83

-2.67 (-0.92%)

11:33
12/13/17
12/13
11:33
12/13/17
11:33
Conference/Events
CoStar Group management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

ROG

Rogers Corporation

$158.59

1.4 (0.89%)

11:30
12/13/17
12/13
11:30
12/13/17
11:30
Conference/Events
Rogers Corporation management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

11:30
12/13/17
12/13
11:30
12/13/17
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ROG

Rogers Corporation

$158.89

1.7 (1.08%)

11:29
12/13/17
12/13
11:29
12/13/17
11:29
Conference/Events
Rogers Corporation management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

HDP

Hortonworks

$19.76

0.18 (0.92%)

11:25
12/13/17
12/13
11:25
12/13/17
11:25
Conference/Events
Hortonworks management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 26

    Feb

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:20
12/13/17
12/13
11:20
12/13/17
11:20
Hot Stocks
Credit Acceptance moves lower following short report from PlainSite »

Shares of Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
12/13/17
12/13
11:17
12/13/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
12/13/17
12/13
11:16
12/13/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$96.15

-3.99 (-3.98%)

11:13
12/13/17
12/13
11:13
12/13/17
11:13
Hot Stocks
Ralph Lauren falls after Bofa/Merrill downgrade cites 'dimming' margin story »

Shares of Ralph Lauren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.58

0.555 (0.91%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Target: Shipt to continue to run business independently post-acquisition »

Shipt will be a wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.48

0.41 (0.65%)

, T

AT&T

$37.75

-0.35 (-0.92%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Cable, telecom stocks dip as T-Mobile plans to bring 'un-carrier' to TV »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$63.48

0.41 (0.65%)

T

AT&T

$37.75

-0.35 (-0.92%)

ROKU

Roku

$46.95

-1.03 (-2.15%)

CMCSA

Comcast

$39.51

1.07 (2.78%)

CMCSK

Comcast

CHTR

Charter

$329.99

-1.5 (-0.45%)

VZ

Verizon

$52.82

-0.375 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

LITE

Lumentum

$51.75

-1.75 (-3.27%)

, FNSR

Finisar

$19.30

-0.51 (-2.57%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Recommendations
Lumentum, Finisar, Apple analyst commentary  »

Apple's investment…

LITE

Lumentum

$51.75

-1.75 (-3.27%)

FNSR

Finisar

$19.30

-0.51 (-2.57%)

AAPL

Apple

$171.70

-0.97 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.73

-0.49 (-0.26%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Periodicals
Netflix executive fired over Masterson assault comments, Page Six says »

Netflix director of kids…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.64

0.62 (1.02%)

11:06
12/13/17
12/13
11:06
12/13/17
11:06
Technical Analysis
Technical View: Target spikes after acquiring Shipt for $550M »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.70

0.68 (1.11%)

11:02
12/13/17
12/13
11:02
12/13/17
11:02
Hot Stocks
Breaking Hot Stocks news story on Target »

Target to bring same-day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.69

0.67 (1.10%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Breaking Hot Stocks news story on Target »

Target: Same-day delivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.72

0.71 (1.16%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Target to buy same-day delivery platform Shipt for $550M in cash »

Target announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYI

Acuity Brands

$165.44

-8.79 (-5.05%)

10:59
12/13/17
12/13
10:59
12/13/17
10:59
Technical Analysis
Technical View: Acuity Brands tumbles, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 09

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.